Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | GAA | P10253 | 4/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | HTT | P42858 | 1/20 | 0.68 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 11/20 | 0.62 |
| ▸ | MAOB | P27338 | 11/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | GUSB | P08236 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4098410 | 1.00 | MEN1 (0.68) | MEN1GAAMAPTKMT2AMAPK1 | |
| SCHEMBL4094410 | 0.90 | MEN1 (0.73) | MEN1GAAMAPTKMT2AMAPK1 | |
| SCHEMBL4094409 | 0.90 | MEN1 (0.73) | MEN1GAAMAPTKMT2AMAPK1 | |
| SCHEMBL4093805 | 0.83 | GAA (0.86) | MEN1GAAMAPTKMT2AMAPK1 | |
| SCHEMBL4093808 | 0.83 | GAA (0.86) | MEN1GAAMAPTKMT2AMAPK1 | |
| SCHEMBL1435442 | 0.81 | MAPT (0.56) | MEN1GAAMAPTKMT2AMAPK1 | |
| SCHEMBL1435501 | 0.81 | MAPT (0.56) | MEN1GAAMAPTKMT2AMAPK1 | |
| SCHEMBL1435444 | 0.79 | MAPT (0.52) | MEN1GAAMAPTKMT2AMAPK1 | |
| SCHEMBL1435490 | 0.77 | GAA (1.00) | MEN1GAAMAPTKMT2AMAOA | |
| SCHEMBL4083570 | 0.77 | GAA (0.79) | MEN1GAAMAPTKMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS PARC SCIENTIFIQUE LUMINY (FR) | 2009-08-13 | — | — | US | claimed |
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | TROPHOS PARC SCIENTIFIQUE LUMINY (FR) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203747-A1 | NOVEL CHEMICAL COMPOUNDS AND THE USES THEREOF AS A MEDICINE | NLN, NQO1, APP | MEN1 1055/4885GAA 157/4885MAPT 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.